Latest American Mental and Medical Health News Thread, FDA Approves Vyvanse(R) (lisdexamfetamine Dimesylate) Capsules CII For The Treatment Of ADHD In Adolescents in Informational; Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced that the US Food and Drug Administration (FDA) ...
-
November 16th, 2010, 10:35 AM
#1
FDA Approves Vyvanse(R) (lisdexamfetamine Dimesylate) Capsules CII For The Treatment Of ADHD In Adolescents
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced that the US Food and Drug Administration (FDA) approved the prescription medication Vyvanse® (lisdexamfetamine dimesylate) Capsules CII for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adolescents ages 13 to 17...
More...
Posting Permissions
- You may not post new threads
- You may not post replies
- You may not post attachments
- You may not edit your posts
-
Forum Rules
LinkBack URL
About LinkBacks
Reply With Quote